{"id":"NCT04534491","sponsor":"Bayer","briefTitle":"Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream.","officialTitle":"An Oxytrol Transdermal System Actual Use Study (Consumer Trial of Oxytrol, Control)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-05-25","primaryCompletion":"2011-06-22","completion":"2011-06-22","firstPosted":"2020-09-01","resultsPosted":"2020-10-20","lastUpdate":"2020-10-20"},"enrollment":855,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Overactive Bladder"],"interventions":[{"type":"DRUG","name":"Oxybutynin (Oxytrol, BAY839380)","otherNames":[]}],"arms":[{"label":"Oxytrol","type":"EXPERIMENTAL"}],"summary":"With this study researchers want to gather information about the consumer use behavior of Oxytrol in a simulated setting in which the medicine is sold directly to a consumer without a prescription from a healthcare professional. An area of focus was on the potential benefits of an over-the-counter status for Oxytrol and on the ongoing use behavior of the consumers. Oxytrol is a thin, flexible, clear patch that is indicated for the treatment of overactive bladder a disease characterized by a collection of symptoms, including urinary frequency, urgency, and urge incontinence. The adhesive patch is placed on the skin to deliver Oxytrol through the skin into the bloodstream.","primaryOutcome":{"measure":"The Percentage of Participants Who Did Not Stop Use When They Either Developed a New Symptom Referred to Anywhere in the Labeling or When Their Condition Worsened Including Abdominal and/or Pelvic Pain.","timeFrame":"Approximately 15 weeks from subjects' initial purchase of Oxytrol","effectByArm":[{"arm":"Oxybutynin (Oxytrol, BAY839380)","deltaMin":14.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":6},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":35,"n":785},"commonTop":["Application site irritation","Urinary tract infection","Nasopharyngitis","Dry mouth","Urge incontinence"]}}